Posts by: Forest Ray PhD

Forest Ray PhD

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

February 22, 2021February 22, 2021

CRISPR Gene Editing Used to Build 1st Model of AML Progression

News

Blocking early inflammatory and innate immune signaling is a promising therapeutic target in acute myeloid leukemia (AML), as disruptions in these signaling pathways occur early and persist throughout the evolution ... Read more

February 15, 2021February 15, 2021

FDA Grants Iadademstat Orphan Drug Designation

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Oryzon Genomics‘ iadademstat, an investigational oral therapy for people with acute myeloid leukemia (AML). “Receiving Orphan Drug ... Read more

January 25, 2021January 25, 2021

COVID-19 Vaccines Pose Little Risk to Rare Disease Patients, FDA, CDC Say

News, syndicated

The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected to pose little risk to the rare disease community, including to ... Read more

December 21, 2020December 21, 2020

NexImmune, City of Hope Partner to Research NEXI-001, New Therapies

News

NexImmune and City of Hope have teamed up on a research initiative aimed at advancing treatment candidate NEXI-001 for acute myeloid leukemia (AML) and identifying new targets for future therapies. ... Read more

December 7, 2020December 7, 2020

First-in-Human Trial Testing NKX101 Natural Killer Cell Therapy Treats First Patient

News

The first patient has received treatment in a first-in-human Phase 1 trial of NKX101, Nkarta‘s investigational cell therapy for the treatment of relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic ... Read more

August 31, 2020August 31, 2020

Same But Different Photo Contest Celebrates People With Rare Diseases

News, syndicated

Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for rare diseases. Under the theme “A ... Read more

August 24, 2020August 24, 2020

Xperiome Platform Aims to Streamline Searches for Rare Diseases, Gain Patient Input

News, syndicated

Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient input ... Read more

July 20, 2020July 20, 2020

New Molecule Shows Promise as Potential Cancer Vaccine for AML

News

Australian scientists have created a promising new vaccine candidate against cancers that express the Wilms’ tumor 1 (WT1) gene. These include cancers of the blood, like acute myeloid leukemia (AML), and ... Read more

July 2, 2020July 2, 2020

Daurismo Combo Approved in Europe for Select Adults With AML

News

Pfizer announced that the European Commission has approved Daurismo (glasdegib) in combination with low-dose cytarabine to treat newly diagnosed acute myeloid leukemia (AML) among adults who are not candidates for ... Read more

June 29, 2020June 30, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

News, syndicated

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for marketed ... Read more